glp-1/gip/glucagon receptor agonist GLP-1 Agonists – Peripheral Brain Targeting GLP-1, GIP & GCG

Type 2 diabetes and glucagon-like peptide-1 receptor agonists Type 2 diabetes is a chronic adverse health condition in which the body either resists the effects of insulin or does not produce enough to keep blood sugar at normal levels

Systematic reviews have revealed that GLP-1RAs exert bidirectional modulatory effects on cancer risk, with outcomes varying depending on cancer type, patient characteristics, and study methodology

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Secondly, they suppress the secretion of glucagon, a hormone produced by the alpha cells of the pancreas that raises blood sugar levels